A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) - SELECT - PsA 1
Phase of Trial: Phase III
Latest Information Update: 12 Oct 2017
At a glance
- Drugs Upadacitinib (Primary) ; Adalimumab
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms SELECT - PsA 1
- Sponsors AbbVie
- 31 Jul 2017 Planned End Date changed from 22 Aug 2022 to 8 Nov 2022.
- 30 Apr 2017 Planned End Date changed from 1 Oct 2022 to 22 Aug 2022.
- 30 Apr 2017 Planned primary completion date changed from 1 Oct 2019 to 23 Oct 2019.